6 questions answered from cited research · Plain language
Real-world data from the BE-FREE study shows that eptinezumab reduces pain intensity and associated symptoms like light sensitivity within 10 to 20 minutes of infusion for patients with ongoing migraine attacks.
Read the full answer →Yes, a 12-week trial found that eptinezumab combined with a brief educational intervention reduced monthly migraine days in adults with chronic migraine and medication overuse.
Read the full answer →Resting-state fMRI shows that people with chronic migraine have lower brain entropy in key brain networks compared to healthy people, and this difference is even greater in chronic migraine than in episodic migraine.
Read the full answer →Yes, intravenous eptinezumab can reduce pain and symptoms during an ongoing chronic migraine attack, with effects seen within 10-30 minutes of infusion.
Read the full answer →Yes, resting-state fMRI shows reduced brain entropy and altered low-frequency brain activity in people with chronic migraine compared to healthy controls.
Read the full answer →Smartphone apps can provide short-term predictions for migraine attacks, but current models only predict about a 59% chance of an attack occurring within 24 hours, which is only slightly better than random guessing.
Read the full answer →